Vericel To Host Virtual Analyst and Investor Day on October 16, 2020
October 09 2020 - 8:30AM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies
for the sports medicine and severe burn care markets, will host a
virtual Analyst and Investor Day on Friday, October 16, 2020, from
9:00 a.m. - 11:00 a.m. ET. During the event, Vericel executives
will provide a general business update as well as current U.S.
commercialization plans for NexoBrid® (concentrate of proteolytic
enzymes enriched in bromelain). Additionally, burn surgeon thought
leaders will discuss current burn debridement practices and how
NexoBrid, upon approval by the U.S. Food and Drug Administration
(FDA), could change the current treatment paradigm for debridement
of severe thermal burns.
The presentation will be live webcast at
http://investors.vcel.com/events-presentations. For those not
available to listen to the live broadcast, a replay will be
archived and available at
http://investors.vcel.com/events-presentations.
About Vericel CorporationVericel is a leader in
advanced therapies for the sports medicine and severe burn care
markets. The company markets two cell therapy products in the
United States. MACI® (autologous cultured chondrocytes on porcine
collagen membrane) is an autologous cellularized scaffold product
indicated for the repair of symptomatic, single or multiple
full-thickness cartilage defects of the knee with or without bone
involvement in adults. Epicel® (cultured epidermal autografts) is a
permanent skin replacement for the treatment of patients with deep
dermal or full-thickness burns greater than or equal to 30% of
total body surface area. The Company also holds an exclusive
license for North American commercial rights to NexoBrid, a
registration-stage biological orphan product for debridement of
severe thermal burns. On September 16, 2020, Vericel announced that
the FDA has accepted a Biologics License Application (BLA) seeking
approval of NexoBrid for eschar removal (debridement) in adults
with deep partial-thickness and/or full-thickness thermal burns.
The FDA has assigned a Prescription Drug User Fee Act (PDUFA)
target date of June 29, 2021. For more information,
please visit the Company’s website at www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel
Corporation. NexoBrid® is a registered trademark of MediWound Ltd.
and is used under license to Vericel Corporation. © 2020 Vericel
Corporation. All rights reserved.
Investor Contacts: Lee SternSolebury
Troutlstern@troutgroup.com+1 (646) 378-2922
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Apr 2023 to Apr 2024